A 61-year-old grandmother from New South Wales is among the first Australians to receive Kisunla, also known as Donanemab, a newly approved treatment for early Alzheimer’s disease. This medication marks the first significant advancement in Alzheimer’s treatment in 25 years and is considered a major breakthrough, according to neurologist Dr Rowena Mobbs.
Dr Mobbs describes the drug and its anti-amyloid class as a significant milestone in the ongoing battle against Alzheimer’s, which has seen more than a century of research without such a direct advancement. One of the first recipients, Jenny Quiring, experienced early symptoms that curtailed her nursing career. She sees this new treatment as a glimmer of hope, emphasised by her husband, James, who noted it’s likely the first real optimism they have encountered.
The treatment allows Jenny the possibility of enjoying more precious moments with her family, including her husband of over four decades, their seven children, and 15 grandchildren. Jenny expressed her desire to witness her grandchildren grow up and achieve happiness.
Initially, the treatment involves monthly infusions which can be expensive, with the total 18-month course and necessary scans amounting to approximately $100,000. However, a government advisory committee is set to review whether Donanemab will be included on the Pharmaceutical Benefits Scheme (PBS), which would make it more accessible. Jenny advocates for its PBS listing, asserting the treatment’s value.
Long-term studies from the manufacturer reveal that the advantages of Donanemab increase over three years and that initiating treatment sooner can decrease the risk of disease progression by 27% compared to postponement.
This new development in Alzheimer’s medication not only provides hope for patients like Jenny but potentially transforms the landscape of treatment for the disease.